Oncology Pharma Inc. announced it is putting together a short list of contract research organizations (CROs) to assist in developing a research plan, along with indications for treatment in developing intellectual property towards commercialization. On February 26, 2021 the company announced that it had signed a worldwide license agreement with SYBLEU Inc. for a combination therapeutic platform for treating cancer. A spokesperson for the company stated it is anticipated there will be several indications this therapeutic will be used for in treating various cancers. It will be the role of the selected CRO to carry out research on behalf of the company. The selected CRO will provide a plan based on its assessment of the intellectual property of Oncology Pharma and assist the company in targeting the first indication for use.